Rheumatology & Autoimmunity (Jun 2024)
Advancements in therapeutic paradigm: Harnessing IL‐17A inhibitor secukinumab to ameliorate psoriasis vulgaris in the presence of resistant pericardial effusion
Abstract
No abstracts available.
Rheumatology & Autoimmunity (Jun 2024)